Alaunos Therapeutics, Inc. (TCRT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alaunos Therapeutics, Inc. on June 19, 2024. The report discloses a change in the Company's independent registered public accounting firm, approved by the Audit Committee.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. However, it notes that the independent auditor's reports for the fiscal years ended December 31, 2023, and 2022, included an explanatory paragraph indicating substantial doubt about the Company's ability to continue as a going concern.
Material Changes
- Dismissal of Auditor: On June 19, 2024, the Company dismissed RSM US LLP as its independent registered public accounting firm.
- Appointment of New Auditor: On June 19, 2024, the Company engaged Cherry Bekaert LLP as its new independent registered public accounting firm.
- No Disagreements: The Company stated there were no disagreements or reportable events with RSM regarding accounting principles, financial statement disclosures, or auditing scope during the fiscal years 2022 and 2023 or the interim period through June 19, 2024.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance or management commentary on future operations. The primary risk highlighted is the previously disclosed "substantial doubt about the Company's ability to continue as a going concern" noted in prior audit reports. The change in auditors is not attributed to any accounting disputes.
Investor Verification Checklist
- Verify the reasons for the change in auditors beyond the stated lack of disagreement.
- Review the most recent financial statements to assess the current status of the "going concern" warning.
- Confirm the engagement terms and scope of the new auditor, Cherry Bekaert LLP.
- Monitor subsequent filings for any updates on the Company's liquidity and capital resources.